Characteristics and Outcomes of a Series of COVID-Associated Mucormycosis Patients in Two Different Settings in Egypt Through the Third Pandemic Wave

References

• Drake TM, Riad AM, Fairfield CJ, et al. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet. 2021;398(10296):223–237. doi:10.1016/S0140-6736(21)00799-6
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615.
   PubMed Web of Science ®Google Scholar
• Aggarwal K, Agarwal A, Jaiswal N, et al. Ocular surface manifestations of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. PLoS One. 2020;15(11):e0241661. doi:10.1371/journal.pone.0241661
   PubMed Web of Science ®Google Scholar
• Sheth JU, Narayanan R, Goyal J, Goyal V. Retinal vein occlusion in COVID-19: a novel entity. Indian J Ophthalmol. 2020;68(10):2291. doi:10.4103/ijo.IJO_2380_20
   PubMed Web of Science ®Google Scholar
• Tisdale AK, Chwalisz B. Neuro-ophthalmic manifestations of coronavirus disease 19. Curr Opin Ophthalmol. 2020;31(6):489–494. doi:10.1097/ICU.0000000000000707
   PubMed Web of Science ®Google Scholar
• Bertoli F, Veritti D, Danese C, et al. Ocular findings in COVID-19 patients: a review of direct manifestations and indirect effects on the eye. J Ophthalmol. 2020;2020:1–9. doi:10.1155/2020/4827304
   Web of Science ®Google Scholar
• Sanghi P, Malik M, Hossain IT, Manzouri B. Ocular complications in the prone position in the critical care setting: the COVID-19 pandemic. J Intensive Care Med. 2020;36(3):361–372. doi:10.1177/0885066620959031
   Web of Science ®Google Scholar
• Alqudah AA, Al Dwairi RA, Alqudah NM, Abumurad SK. COVID-19 lockdown and eye injury: a case series from Jordan. Int Med Case Rep J. 2020;13:493–501. doi:10.2147/IMCRJ.S274284
   Web of Science ®Google Scholar
• Pichi F, Aljneibi S, Neri P, Hay S, Dackiw C, Ghazi NG. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol. 2021;139(10):1131–1135. doi:10.1001/jamaophthalmol.2021.3477
   PubMed Web of Science ®Google Scholar
• Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020;6(4):265. doi:10.3390/jof6040265
   Web of Science ®Google Scholar
• Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.e5–264.e8. doi:10.1016/j.ajem.2020.09.032
   PubMed Web of Science ®Google Scholar
• Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186(2):289–298. doi:10.1007/s11046-021-00528-2
   PubMed Web of Science ®Google Scholar
• Narayanan S, Chua JV, Baddley JW. COVID-19 associated mucormycosis (CAM): risk factors and mechanisms of disease. Clin Infect Dis. 2021. doi:10.1093/cid/ciab726
   PubMed Web of Science ®Google Scholar
• Pandiar D, Kumar NS, Anand R, Kamboj M, Narwal A, Shameena PM. Does COVID 19 generate a milieu for propagation of mucormycosis? Med Hypotheses. 2021;152:110613. doi:10.1016/j.mehy.2021.110613
   PubMed Web of Science ®Google Scholar
• Pasternak M, Olszanecki R. Mucormycosis in head and neck area - the emerging health problem in COVID-19 pandemic. The perspective of a dental practitioner. Folia Med Cracov. 2021;61(2):117–127. doi:10.24425/fmc.2021.137228
   Google Scholar
• Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev. 2021;15(4):102146. doi:10.1016/j.dsx.2021.05.019
   PubMed Web of Science ®Google Scholar
• Selarka L, Sharma S, Saini D, et al. Mucormycosis and COVID‐19: an epidemic within a pandemic in India. Mycoses. 2021;64(10):1253–1260. doi:10.1111/myc.13353
   Web of Science ®Google Scholar
• Fouad YA, Abdelaziz TT, Askoura A, et al. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. Front Med. 2021;8:716. doi:10.3389/fmed.2021.645270
   Web of Science ®Google Scholar
• Rabagliati R, Rodríguez N, Núñez C, Huete A, Bravo S, Garcia P. COVID-19-associated mold infection in critically ill patients, Chile. Emerg Infect Dis. 2021;27(5):1454–1456. doi:10.3201/eid2705.204412
   Web of Science ®Google Scholar
• Pakdel F, Ahmadikia K, Salehi M, et al. Mucormycosis in patients with COVID‐19: a cross‐sectional descriptive multicentre study from Iran. Mycoses. 2021;64(10):1238–1252. doi:10.1111/myc.13334
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K, Wadman M. Delta variant triggers new phase in the pandemic. Science. 2021;372(6549):1375. doi:10.1126/science.372.6549.1375
   Web of Science ®Google Scholar
• Del Rio C, Malani PN, Omer SB. Confronting the delta variant of SARS-CoV-2, Summer 2021. JAMA. 2021;326(11):1001. doi:10.1001/jama.2021.14811
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405–e421. doi:10.1016/S1473-3099(19)30312-3
   PubMed Web of Science ®Google Scholar
• Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e197. doi:10.1016/S1473-3099(20)30483-7
   PubMed Web of Science ®Google Scholar
• Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021;186(6):739–754. doi:10.1007/s11046-021-00584-8
   PubMed Web of Science ®Google Scholar
• Thiagarajan K. Why is India having a covid-19 surge? BMJ. 2021;373:n1124. doi:10.1136/bmj.n1124
   PubMed Web of Science ®Google Scholar
• Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol. 2021;69(7):1670–1692.
   PubMed Web of Science ®Google Scholar
• Hussain S, Baxi H, Riad A, et al. COVID-19-associated mucormycosis (CAM): an updated evidence mapping. Int J Environ Res Public Health. 2021;18(19):10340. doi:10.3390/ijerph181910340
   PubMed Web of Science ®Google Scholar
• Avatef Fazeli M, Rezaei L, Javadirad E, et al. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: an observational study. Mycoses. 2021;64(11):1366–1377. doi:10.1111/myc.13351
   Web of Science ®Google Scholar
• Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19 associated mucormycosis: a life-threatening complication in patients admitted with severe to critical COVID-19 from Pakistan. Clin Microbiol Infect. 2021;27(11):1704–1707. doi:10.1016/j.cmi.2021.07.038
   Web of Science ®Google Scholar
• Ashour MM, Abdelaziz TT, Ashour DM, Askoura A, Saleh MI, Mahmoud MS. Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature. J Neuroradiol. 2021;48(5):319–324. doi:10.1016/j.neurad.2021.05.007
   PubMed Web of Science ®Google Scholar
• El-Kholy NA, El-Fattah AMA, Khafagy YW. Invasive fungal Sinusitis in post COVID-19 patients: a new clinical entity. Laryngoscope. 2021;131(12):2652–2658. doi:10.1002/lary.29632
   PubMed Web of Science ®Google Scholar
• Alfishawy M, Elbendary A, Younes A, et al. Diabetes mellitus and Coronavirus disease (Covid-19) associated mucormycosis (CAM): a wake-up call from Egypt. Diabetes Metab Syndr. 2021;15(5):102195. doi:10.1016/j.dsx.2021.102195
   Web of Science ®Google Scholar
• Assaad Khalil SH, Megallaa MH, Rohoma KH, et al. Prevalence of type 2 diabetes mellitus in a sample of the adult population of Alexandria, Egypt. Diabetes Res Clin Pract. 2018;144:63–73. doi:10.1016/j.diabres.2018.07.025
   PubMed Web of Science ®Google Scholar
• AlSawahli H, Mpyet CD, Ezzelarab G, et al. Population-based cross-sectional prevalence survey of diabetes and diabetic retinopathy in Sohag—Egypt, 2019. BMJ Open. 2021;11(6):e047757. doi:10.1136/bmjopen-2020-047757
   Web of Science ®Google Scholar
• Arora S, Hemmige VS, Mandke C, et al. Online Registry of COVID-19–associated mucormycosis cases, India, 2021. Emerg Infect Dis. 2021;27(11):2963–2965. doi:10.3201/eid2711.211322
   Web of Science ®Google Scholar
• Farias LABG, Damasceno LS, Bandeira SP, Barreto FKDA, Leitão TDMJS, Cavalcanti LPDG. COVID-19 associated mucormycosis (CAM): should Brazil be on alert? Rev Soc Bras Med Trop. 2021;54:e04102021. doi:10.1590/0037-8682-0410-2021
   Web of Science ®Google Scholar